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Abstract
Background: Up-to-date, high quality, evidence-based clinical practice guidelines (CPGs) that are applicable for
primary healthcare are vital to optimize services for the population with chronic musculoskeletal pain (CMSP). The
study aimed to systematically identify and appraise the available evidence-based CPGs for the management of
CMSP in adults presenting in primary healthcare settings.
Methods: A systematic review was conducted. Twelve guideline clearinghouses and six electronic databases were
searched for eligible CPGs published between the years 2000 and May 2015. CPGs meeting the inclusion criteria
were appraised by three reviewers using the Appraisal of Guidelines Research and Evaluation (AGREE) II.
Results: Of the 1082 records identified, 34 were eligible, and 12 CPGs were included based on the inclusion and
exclusion criteria. The methodological rigor of CPG development was highly variable, and the median domain score
was 66%. The median score for stakeholder involvement was 64%. The lowest median score was obtained for the
domain applicability (48%). There was inconsistent use of frameworks to aggregate the level of evidence and the
strength of the recommendation in the included CPGs. The scope and content of the included CPGs focussed on
opioid prescription.
Conclusion: Numerous CPGs that are applicable for the primary healthcare of CMSP exists, varying in their scope
and methodological quality. This study highlights specific elements to enhance the development and reporting of
CPGs, which may play a role in the uptake of guidelines into clinical practice. These elements include enhanced
reporting of methodological aspects, the use of frameworks to enhance decision making processes, the inclusion of
patient preferences and values, and the consideration of factors influencing applicability of recommendations.
Trial registration: PROSPERO CRD42015022098.
Keywords: Clinical practice guidelines, Chronic musculoskeletal pain, Primary health, Systematic review
Background
Chronic musculoskeletal pain (CMSP) is a global health-
care concern. The condition is classified as a part of
chronic non-malignant pain, which encompasses muscu-
loskeletal, neuropathic and visceral pain, and pain from
sickle cell disease [1]. CMSP negatively impacts physical
and psychosocial health, daily function, participation in
life roles, healthcare utilization, health-related quality of
life [2–4]; and its management is associated with high
financial, personal and resource costs. This complex
condition involves biological, psychological, social and
environmental factors. Therefore, a multidisciplinary and
holistic approach to the management of CMSP is appro-
priate [5].
The prevalence of chronic pain is high and increasing
[2, 6, 7]. A large proportion of individuals with CMSP
present in primary healthcare settings for management
[3, 8]. Primary healthcare settings appears to be ideally
* Correspondence: dd2@sun.ac.za
1Division of Physiotherapy, Faculty of Medicine and Health Sciences,
Stellenbosch University, PO Box 241, Cape Town 8000, South Africa
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ernstzen et al. Implementation Science  (2017) 12:1 
DOI 10.1186/s13012-016-0533-0
situated to deliver holistic care for the patient with
chronic pain, addressing the health needs within the
community [9], while integrating preventative, promo-
tive, curative, and rehabilitation services. The compo-
nents of primary healthcare are congruent with the
proposition that chronic pain management should be
multimodal and include rehabilitative options [1, 3, 10].
It is therefore vital that primary healthcare settings are
adequately resourced to deal with the service-provision
load associated with the holistic management of CMSP
[3, 11]. These resources may include human resources,
healthcare system, and policy and information resources.
Access to high quality, evidence-based, and up-to-date
information resources can assist clinicians in making
decisions about the care of patients with CMSP. Clinical
practice guidelines (CPG) are one way of providing infor-
mation on evidence-based and person-centred options for
CMSP care. CPGs provide systematically developed
clinical recommendations derived from best available
evidence to guide clinicians and patients in making deci-
sions about healthcare for specific clinical circumstances
[12, 13]. CPGs may support decision-making by managers
and policy-makers about the organization and delivery of
healthcare [12, 14]. The implementation of CPGs can
optimize healthcare by improving the quality, consistency,
appropriateness, and cost-effectiveness of care [15–18].
Furthermore, CPGs play a role in enhancing provider and
patient satisfaction with care [18]. CPGs are therefore
useful means to enhance quality healthcare for the patient
with CMSP by implementing evidence-informed manage-
ment. Ideally, CPGs about CMSP should include a
multidisciplinary perspective to facilitate the holistic
management of CMSP.
The validity of CPGs depends on how well they were
designed and conducted [14]. Clinicians often find it dif-
ficult to judge a CPG as trustworthy or of good quality
due to the large number of CPGs available and the often
contradictory information in them [13, 17]. In a good
quality CPG, the clinical recommendations are rigor-
ously developed, based on current, relevant scientific
evidence, and it considers the benefits and harms of dif-
ferent healthcare options [13, 17, 19, 20]. Good quality
CPGs encourage the use of interventions with proven
benefits and discourages the use of ineffective or harm-
ful interventions [21]. The cost-effectiveness of im-
plementation, context-specific factors, and stakeholder
involvement are important elements to be considered by
a good CPG [20]. Despite the above quality indicators,
several authors found the methodological quality of
CPGs to be highly variable [16, 18, 20]. Consequently
and several criteria have been developed to evaluate the
methodological quality of CPGs, for example, the AGREE
(Appraisal of Guidelines Research and Evaluation) instru-
ment [13, 20, 22].
High quality, evidence-based, and up-to-date CPGs
that are applicable for primary healthcare are crucial to
optimize care for CMSP [7]. The multidimensional na-
ture of CMSP, together with its associated burden,
heightens the need for multimodal management strat-
egies to prevent and manage the condition. A CPG is an
important information resource to facilitate decision-
making about care and to translate research findings
into clinical practice. When considering the develop-
ment of a CPG for the management of CMSP in primary
healthcare, one needs to consider if such CPGs already
exist, if existing CPGs are of high quality and if it repre-
sents the holistic and multimodal management for
CMSP. The de novo development of CPGs can be
expensive and time-consuming. Consequently, it has be-
come a viable option to adopt, adapt, or contextualize
existing CPGs in resource-constrained environments
[23]. CPG contextualization refers to the consideration
of possible differences in contextual factors such as per-
sonal and environmental features that may differ from
one setting to the other. Knowledge about the existence
and quality of CPGs for CMSP in primary healthcare, can
inform the choice between adoption, adaptation, con-
textualization and de novo development of CPGs. The
aim of this systematic review was therefore to methodic-
ally identify and appraise the available evidence-based
CPGs for the management of adults with CMSP in pri-
mary healthcare settings.
The primary objectives were to:
 identify profession-specific or inter-professional
CPGs on the management of CMSP in primary
healthcare settings;
 critically appraise the quality of the included CPGs
using the AGREE II instrument;
 determine the currency of the CPGs; and to
 determine the grading systems used to demarcate
the level of evidence and the strength of the
recommendation in the CPGs.
Methods
Study criteria
The study criteria were formulated using the PIPOH for-
mat (population, intervention, professions, health out-
comes and health setting) for guideline reviews [24]. The
types of studies eligible were CPGs available in full text
and published between the years 2000 and May 2015. The
date cut-off was set to ensure up-to-date CPGs. The target
population and disease characteristic of the CPGs included
adults with CMSP. It was anticipated that recommenda-
tions for CMSP would be included in CPGs for chronic
non-malignant pain. CPGs that focused exclusively on
chronic pain from non-musculoskeletal origin such as
sickle cell disease, neuropathic pain, and malignancy was
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excluded due to the differences in pathology, pain mecha-
nisms, and possible management strategies.
The types of interventions could include evaluation,
diagnosis, and management of CMSP. Examples of such
interventions include inter-professional interventions,
pharmacological, and non-pharmacological management,
rehabilitative options, and self-management. CPGs that tar-
geted any healthcare professionals involved in the manage-
ment of CMSP were eligible for inclusion. The expected
outcomes of CPGs could include patient outcomes, system
outcomes, or public health outcomes. For the purpose of
this review, only CPGs focused on primary healthcare set-
tings were included. CPGs that focussed solely on second-
ary, tertiary, or specialist healthcare settings were excluded
due to different management options offered.
Search strategy
The primary investigator searched the electronic databases
of the following guideline clearinghouses: the US National
Guideline Clearinghouse (US NGC); Agency for Healthcare
Research and Quality (AHRQ); Guidelines International
Network (G-I-N); Scottish Intercollegiate Guidelines
(SIGN); United Kingdom’s National Institute for Health
and Clinical Excellence (NICE); New Zealand Guidelines
Group (NZGG); WHO guidelines; TRIP database; National
Institutes of Health (NIH); Monash University Centre for
Clinical Effectiveness; Australia’s National Health and
Medical Research Council (NHMRC); Canadian Medical
Association Clinical Practice Guidelines Infobase, and the
Institute for Clinical Systems Improvement (ICSI). In
addition, the following online databases were searched to
include those guidelines that were peer reviewed and pub-
lished in journals: CINAHL, PEDro; PubMed, EBSCO host,
and Medline. The broad search terms included: clinical
practice guidelines; OR clinical guidelines; OR care path-
way; OR clinical pathway; OR care protocol; AND chronic
pain; OR chronic musculoskeletal pain; OR chronic non-
malignant pain; OR chronic non-cancer pain; AND adults;
AND primary care; OR primary healthcare.
The initial search was conducted from July to October
2014, and the search was updated during May 2015. The
inclusion and exclusion criteria were applied by screen-
ing the identified CPG titles and objectives to select the
eligible CPGs. The data was extracted in the PIPOH for-
mat to enable this analysis. The process was verified by
the co-authors on a random audit basis. A record of
search yields and decision-making was kept.
Data extraction
The primary investigator extracted the following data
into custom built data extraction sheets:
 The clinical question formulation using the PIPOH
format.
 Guideline currency: the publication date of the CPG
and periods covered by the literature search in the
guideline, date of revision.
 General information: the developing organization/
authors; country of publication; language of
publication.
Critical appraisal
The methodological quality of eligible CPGs was inde-
pendently assessed by three reviewers using the AGREE
II instrument [25]. The AGREE II is an internationally
developed, widely accepted, valid, reliable, easy to use,
and transparent instrument to assess the methodological
rigor of the reported guideline [18, 22]. It contains 23
key quality items categorized in six domains, scored on a
7-point Likert scale. The AGREE II evaluates the process
of CPG development and the quality of reporting. How-
ever, it does not evaluate the content of the CPG, nor
the quality of evidence supporting the recommendations.
Each AGREE II domain focuses on a separate aspect of
guideline quality, namely, scope and purpose, stake-
holder involvement, rigor of development, clarity of
presentation, applicability, and editorial independence.
The reviewers’ AGREE scores were entered into a cus-
tom built Excel spreadsheet by the primary investigator.
Any difference in score higher than two points was dis-
cussed amongst the project team to reach consensus. A
quality score was calculated for each of the six AGREE
II domains using the guiding principles and the follow-
ing formula provided in the user manual:
Domain score = (obtained score–minimum possible
score)/(maximum possible score–minimum possible
score) × 100 = %. All item scores in a domain were
summed, and the total was standardized as a percentage
of the maximum possible score for that domain. The
median domain score and interquartile range (IQR) for
each domain was then calculated [26].
Results
Search results
The results of the systematic search are summarized in
Fig. 1. The search yielded two categories of CPGs,
namely, comprehensive CPGs and CPGs that were pub-
lished in journal article format. Where indicated, contact
was made with the authors to obtain full text CPGs.
Thirty-four eligible CPG were considered for inclusion.
After applying the inclusion/exclusion criteria, 12 CPGs
were included. The main reasons for exclusions are sum-
marized in Fig. 1.
Included clinical practice guidelines
Table 1 summarizes information about the included
CPG and their currency. One of the included CPGs orig-
inated from a middle-income country (CPG 10). Six out
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of the 12 included CPGs focused on the prescription of
opioids (CPGs 1, 3, 6, 7, 8, and 10), and two focused spe-
cifically on the management of musculoskeletal pain
(CPG 9 and 12).
Methodological quality
The AGREE II domain scores (median and range) are pro-
vided in Table 2. The domains with the lowest median
score were domain 2 (stakeholder involvement), domain 3
(rigor of development), and domain 5 (applicability).
Further analysis of each question within a domain is
represented in Table 3. Additional file 1 provides more
information on the guideline development group and the
stated scope for each CPG.
CPGs consistently inadequately adhered to topic 5 in
domain 2 (views and preferences of target population).
Only 3 of the 12 included CPGs reported that they
sought patient perspectives as part the CPG develop-
ment. The methods used in these CPGs included focus
groups with patients (CPGs 3 and 2); patients as part of
the guideline development group (CPG 5); a literature
search of patients’ preferences (CPG 5); an environmen-
tal scan through surveys, key informant interviews and
focus groups (CPG 2). The strengths and limitations of
evidence (topic 9), was also inconsistently adhered to.
Within domain 3 (rigor of development), topic 14 had
the lowest scores, indicating that few CPGs included a
procedure for updating the CPG. All four topics in do-
main 5 (applicability) were challenging for the CPG de-
velopers to report on, as indicated by the low scores.
The analysis of domain 5 (applicability) indicated that
algorithms and outcome measure tools for putting rec-
ommendations into practice was the most common
strategies provided to facilitate implementation of CPG
Fig. 1 Diagram of search results (PRISMA format)
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recommendations (see Additional file 2). Although
guideline developers mentioned barriers and facilitators
for the use of the CPG (CPG 1, 3, 4, 5); this aspect was
not covered in-depth. The consideration of resource
implications was partially covered. Policies, as well as
monitoring and evaluation criteria for opioid therapy was
a consideration that was well attended to by the CPGs
focusing on opioid prescription (CPG 1, 2, 6, 7, and 8).
Evidence grading systems used by the clinical practice
guidelines
The CPGs used a variety of grading systems to
categorize the levels of evidence and the strength of the
recommendation. These grading systems are sum-
marised in Table 4. Three CPGs did not grade the level
of evidence or the strength of the recommendation. Four
CPGs graded the level of evidence, but not the strength
of the recommendation.
Guideline content overview
Table 5 provides a content overview of the included
CPGs. In CPG 7, 9, 10, 11, and 12, no clear recommen-
dation statements were identifiable, and therefore an
overview is presented. The writing style of these CPGs
focused on a discussion of relevant information, and was
less focused on making clear recommendations. The
content of the CPGs focused on assessment of CMSP
and on the prescription of opioids. Eight out of the 12
CPGs included at least one position statement about re-
habilitation options for CMSP.
Discussion
This systematic review, to the knowledge of the authors, is
the first to focus on identifying and appraising profession-
specific and inter-professional CPGs for the management
of CMSP in the primary healthcare settings. One of the
main findings was that there are multiple, current CPGs
on the topic that had been developed by different organi-
zations and authors. Considerable time, effort, and re-
sources were therefore invested in the development of
these CPGs. Two guidelines focus specifically on CMSP
management in primary healthcare, and recommenda-
tions for the management of CMSP were imbedded in the
CPGs for chronic non-malignant pain. CPGs were mainly
profession-specific, few took a multidisciplinary per-
spective, and CPGs varied in their scope, coverage, format,
and quality.
The scope of the majority of included CPGs focused
on opioid prescription and congruently, the content of
the CPGs is also focused on opioid prescription (Tables 1
and 5, Additional file 1). The focus on opioid prescrip-
tion can be ascribed to the dramatic rise in the pres-
cription of opioids, as a result of the increase in the
prevalence of chronic pain and the increase in dosage
and frequency of prescription [10, 27–29]. The risks as-
sociated with opioid use may have created a growing
need for clinical guidance on decision-making for opioid
prescription. It is thus likely that high quality, evidence-
based CPGs became fundamental to provide guidance for
the safe prescription of opioids for CMSP. In contrast,
although included CPGs advocated non-pharmacological
management options for the management of CMSP in pri-
mary healthcare, recommendations about these options
were seldom included. SIGN [30], ICSI [31], and RNAO
[32] provided multiple recommendations on various
rehabilitation options, while Sanders et al. [33] and
Schnitzer [7] mentioned multimodal options. The lack of
focus of non-pharmacological management options was
congruent with the inadequate representation of rehabili-
tation practitioners in the guideline development teams of
included CPGs. Since several high quality CPGs are now
available for the prescription of opioids, we recommend
the future guidelines should include a holistic and multi-
disciplinary scope. The prevention and management of
CMSP requires a holistic and inter-/multidisciplinary
approach to address the complex interaction between
biological, psychological, social and environmental factors
[5]. We argue that a renewed scope on holistic manage-
ment, with a congruently aligned multidisciplinary guide-
line development team, is needed for future CPGs on the
primary healthcare of CMSP, to address the burden associ-
ated with the condition.
Table 2 Combined scores of the three reviewers in %
CPG 1 CPG 2 CPG 3 CPG 4 CPG 5 CPG 6 CPG 7 CPG 8 CPG 9 CPG 10 CPG 11 CPG 12 Median IQR
Domain 1: scope and purpose 89 96 98 80 93 48 89 76 67 78 63 48 79 24
Domain 2: stakeholder involvement 65 85 91 70 100 52 63 80 57 35 22 15 64 34
Domain 3: rigor of development 72 85 94 88 94 47 40 84 60 30 51 30 66 41
Domain 4: clarity of presentation 91 89 87 96 98 87 69 90 83 69 57 72 87 19
Domain 5: applicability 60 79 75 92 79 53 32 43 21 14 15 7 48 57
Domain 6: editorial independence 97 100 100 67 67 97 44 100 25 100 0 86 91.5 39
TOTAL 474 534 545 493 531 384 337 473 313 326 208 258
Overall score out of 7 5 5.6 6 5.3 6.5 4 3.6 5 3.6 3 3 3
CPG clinical practice guideline
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The review revealed three AGREE II domains that require
consideration to enhance the quality of future CPGs for
CMSP in primary healthcare settings, namely, the domains
of rigor of development, stakeholder involvement, and ap-
plicability. The findings are congruent with that of Shaneyfelt
et al. [16] and Misso et al. [34]. Shaneyfelt et al. [16] reviewed
279 CPGs to determine adherence to quality standards. They
identified aspects needing improvement in the reviewed
CPG as: the identification of evidence, the formulation of
recommendations, guideline expiry date, cost implications,
and the role of values and preferences. Misso et al. [34]
reviewed CPGs for osteoarthritis of the knee and hip and
found stakeholder involvement, rigor of development, applic-
ability. and editorial independence to be poorly addressed.
In our review, the median score for reporting of rigor
of development (domain 3) was adequate; however, the
range of these scores was wide. The criteria that
presented challenges were the aggregation of the
strengths and limitations of the body of evidence and
updating the CPG. More than half of the included CPGs
were current and were published 5 years prior to our
systematic search. Guideline developers put little em-
phasis on providing procedures and dates for updating
the CPGs, which was also a key deficiency found in Ver-
nooij’s et al. [35] systematic review of guideline hand-
books. Providing details about updating a CPG is
important, because they may become outdated as new
evidence for interventions become available, emphasiz-
ing the need for recommendations to be modified [13,
15]. We recommend that the domain of methodological
rigor should receive detailed consideration during future
CPG development to improve the credibility of the evi-
dence base on which recommendations are built. Not
adhering to the criteria of this domain may threaten
Table 4 Grading systems used to determine the level of evidence and the strength of the recommendation
CPG Name of grading system Level of evidence grading Strength of recommendation






2 ICSI [31] In transition between ISCI system to GRADE.



































7 WSAMDG [44] Rating scheme (not provided) Not provided None
8 APS AAP
[45]













10 Raff [48] – None None
11 Sanders [33] – None None
12 Schnitzer [7] – None None
CPG clinical practice guideline
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the trustworthiness and consequently uptake of CPG
recommendations in primary healthcare practice. A
thorough, unbiased review and aggregation of the evi-
dence may prevent incorrect or biased recommenda-
tions [14].
This systematic review highlights the inconsistent use of
frameworks to aggregate the level or body of evidence and
the strength of the recommendation by the included CPGs.
The criterion of using a framework to rate the strengths
and limitations of the body of evidence is evaluated in the
AGREE II domain of methodological rigor (topic 9). The
AGREE II considers formal or informal methods for this
domain. A framework that guides the decision-making
process for recommendations ensures transparency and ob-
jectivity [14] and provides logical methods for considering
the entire body of evidence relevant to a particular clinical
question. Determining the body of evidence that underpins
a CPG recommendation is critical in the guideline develop-
ment process. Without transparency of the framework used
to aggregate the body of evidence, guideline users cannot
determine whether recommendations are built on strong
evidence or weak evidence [14]. Furthermore, few included
CPGs used the body of evidence together with the strength
of the recommendation to frame recommendations. Deter-
mining the strength of the recommendation guides the ap-
plicability and implementability of the recommendations.
The strength of the recommendation is dependent on the
quality of the evidence, the balance between desirable and
undesirable effects, values and preferences of the stake-
holders and cost of implementation [36]. During the devel-
opment of FORM (Australian method for formulating and
grading recommendations), several efficient frameworks
for developing recommendations were identified [37].
These frameworks included GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation),
SIGN (Scottish Intercollegiate Guidelines) and SORT
(Strength-of-Recommendation Taxonomy) [37]. The
frameworks consider the evidence base (study quality, size,
precision of results, bias); the consistency of different study
findings; the clinical impact based on the body of evidence;
generalizability of the results; and the applicability to the
context that it is intended for [37]. The process of guide-
line development is evolving, and recently, more emphasis
has been placed on the decision-making process of moving
from evidence to recommendations. The use of evidence
to decision frameworks is advocated as a systematic and
transparent process to formulate recommendations [38].
In the review, guideline developers reported to use formal
or informal consensus processes to make decisions. How-
ever, the use of evidence to decision frameworks was not
explicitly stated in the included CPGs (also not a criterion
for AGREE II). CPGs using GRADE (see Table 4), may
have used a framework to consider factors that influence
the strength and direction of the recommendation. The
use of frameworks or a writing guide to frame recommen-
dations, to grade the body of evidence and to determine
the strength of the recommendation is advocated as a way
to ensure consistency and transparency when making de-
cisions and writing recommendations. Guideline devel-
opers are encouraged to use frameworks such as FORM,
GRADE, SIGN, and SORT to enhance systematic
decision-making processes in CPG construction.



























ASIPP ICSI NOUGG RNAO SIGN UMHS WSA MDGa APS-AAP Harrisa Raffa Sandersa Schnitzera
Evaluation/assessment √ √ √ √ √ √ √ √ √ √ 10 83
Diagnosis √ √ √ √ √ √ 6 50
Planning of care √ √ √ √ √ √ √ √ 8 67
Complementary therapy √ √ 2 17
Diet therapy √ √ 2 17
Practitioner education √ 1 8
Occupational therapy √ √ 2 17
Organization and Policy √ 1 8
Pharmacological therapy
(non-opioids)
√ √ √ √ √ √ √ 7 58
Pharmacological therapy
(opioids)
√ √ √ √ √ √ √ √ √ √ √ 11 92
Physical therapy √ √ √ √ √ √ √ √ 8 67
Psychologically based
therapy
√ √ √ √ √ √ 6 50
CPG clinical practice guideline
aNo clear recommendation statements
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The inclusion of stakeholders in the development
process of CPGs is assessed as part of AGREE II
(domain 2), and adherence to this quality criterion is
thought to enhance a sense of ownership, thereby facili-
tating the uptake of the guideline [19]. While most in-
cluded CPGs representation from professional groups,
guideline developers did not commonly include the
views and preferences of the target populations (patients
and public). Shaneyfelt et al. [16] and Misso et al. [34]
likewise found that patient values and preferences were
not effectively addressed during CPG development. Pa-
tient perspectives and preferences influences healthcare
utilization, therefore, patient perspectives about CMSP
and its treatment are important in CPG development
[20]. Patient preferences and concerns are shaped by
context factors, which in turn impact the formulation
and applicability of guideline recommendations. Conse-
quently, some recommendations in a CPG may be pref-
erence sensitive. The inclusion of patient perspectives in
the guideline development process is an important step
towards facilitating relevant, person-centred care, and
autonomy [39].
The AGREE domain of applicability (relevance) considers
context factors that may impact CPG implementation,
namely, the facilitators, barriers, and resource implications
for implementation; tools for putting recommendations
into practice, as well as monitoring and auditing criteria
that influence the uptake and implementation of a CPG.
These criteria therefore represent the features of the health-
care system, resources, cultural, and organizational factors
that should be considered in framing guideline recommen-
dations [15, 17, 19, 36]. Gagliardi et al. [12] contends that
information on implementability within a CPG may assist
the end-users to adopt the recommendations. In this re-
view, the domain of applicability received the lowest me-
dian score. It is plausible that context features were not
included in the CPG document, but were a part of the im-
plementation plan for the CPG in a particular setting. The
RNAO [32] and SIGN [30] contend that each setting/insti-
tution may benefit from a tailor-made implementation plan.
Participation of local stakeholders can ensure that the CPG
and its recommendations are compatible with the local
context. It is possible that explicit statements on implemen-
tation parameters were not included as they may differ
from one setting to the other. Additionally, the use of evi-
dence to decision frameworks considers population or
patient-specific outcomes, including cost-effectiveness, ap-
plicability, feasibility, subgroups, and generalizability when
framing recommendations [37, 38]. The use of these frame-
works may provide useful information about the context
and application of recommendations, which may enhance
CPG quality and uptake, and inform processes such as
CPG adoption, adaptation, and contextualization [23, 24].
Regardless of the use of frameworks, it is advisable that
future CPG on CMSP include more information on poten-
tial resource implications and barriers and facilitators to
implementation.
Transparency and specificity regarding context factors
that may impact recommendations is becoming increas-
ingly important due to the option of adopting, adapting,
or contextualizing CPGs for different settings, when de
novo development of CPGs is not a feasible option. Know-
ledge about the context sensitive recommendations, may
inform the above processes of CPG development. It is
therefore an option that future CPGs on CMSP highlights
preference or context sensitive recommendations [39];
and link these recommendations to context applicable im-
plementation strategies, since context factors may play a
vital role in applicability. An example of signposting con-
text sensitive recommendations, is illustrated in the novel
concept of CPG contextualization, whereby context and
practice points are produced and linked to relevant con-
text sensitive recommendations [23, 40]. The inclusion of
context and practice points is thought to enhance CPG
the application of recommendations in practice.
CPGs can be an important information resource for the
evidence-based and holistic management of CMSP and
has the potential to influence policy and practice about
CMSP care. Given the multidimensional nature of CMSP,
it is important that the scope of future CPGs include a
multidisciplinary approach, which implies that healthcare
systems in which CMSP is managed should ideally allow
for a multidisciplinary management approach. While
some included CPGs elaborated on the cost and cost-
effectiveness of interventions, the findings of this review
indicate that there is great opportunity for CPGs to
elaborate on cost and policy implications that guideline
recommendations may have. The RNAO [32] included
the potential impact of CPG recommendations on policy,
legislation, healthcare systems, and health professions
education for CMSP. One policy aspect that was well
addressed in the CPGs was the need for policy on the pre-
scription and monitoring of opioids for CMSP. The inclu-
sion of information on policy and practice implications is
useful and may play a role in the organizational accept-
ance and implementation of the CPG.
We identified several strengths in the CPGs, which in-
cluded that guideline developers clearly communicated
the overall objectives, scope, and focus of the CPG. The
domain on clarity of presentation obtained a high score,
indicating that CPGs presented their recommendations
in a clear, easily identifiable, and specific format. Editor-
ial independence had also been adhered to in most in-
cluded CPGs.
Implications for practice
This systematic review highlights the strengths and limi-
tations of current CPGs on the management of CMSP in
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primary healthcare settings. Guideline developers who
are considering adopting, adapting, contextualizing, up-
dating existing CPGs, or developing new CPGs for
CMSP should consider the findings of this systematic re-
view to optimize the methodological quality and uptake
of CPGs. Based on the findings of this review, the
authors recommend that future CPGs should:
 Include decision-making frameworks for the level of
evidence, strength of recommendation, and framing
recommendations in the CPG development process.
 Include the relevant stakeholders and end-users in
the process of CPG development.
 Consider and document barriers and facilitators that
may influence the uptake of clinical guideline
recommendations in the intended setting.
 Develop and document strategies to facilitate the
successful uptake and implementation of CPGs into
practice.
 Provide dates and procedures for updating the CPG.
We further recommend that, due to the many CPGs
on the topic, existing high quality CPGs be contextual-
ized to local circumstances, particularly in resource-
constrained environments. In this way, resources may be
used to further the uptake of CPG recommendations
with a rigorous implementation and sustainability strat-
egy, instead of resources being spent on de novo CPG
development [23]. Where de novo development of CPGs
are feasible and the focus should be on a multidisciplin-
ary scope. We found that CPGs written in the article for-
mat had several limitations that can be attributed to the
restrictions of the journal. We recommend that in the
case of a journal format, supplementary material be
made available about methodological development.
The similarities between the findings of this systematic
review and that of Shaneyfelt et al. [16] and Misso et al.
[34] indicate after more than a decade guideline devel-
opers are still finding it challenging to adhere to certain
quality standards of developing CPGs. The reasons for
this phenomenon warrant further investigation.
Limitations
Our review had some limitations of its own. We applied
the AGREE II instrument, which evaluates the reported
rigor of development and not the content of the CPG.
The next step in our process is the content analysis of
high quality CPGs for CMSP in primary healthcare set-
tings. Our focus was specific to primary healthcare set-
tings, and this may have excluded some guidelines that
are applicable in this setting, but not stated overtly to be
so. The CPGs we identified were predominantly from
developed countries, so the appropriateness of these
guidelines in other countries is uncertain. Furthermore,
we acknowledge that although we did an extensive lit-
erature search, we may have missed eligible CPGs.
Conclusion
The systematic review found several CPGs that are applic-
able for the primary healthcare of CMSP. The included
CPGs vary in their scope and methodological rigor. There
was little emphasis on non-pharmacological strategies in
the composition of the guideline development team, the
stated scope, and the content of the CPGs.This study
highlights specific elements for enhancement in the devel-
opment and reporting of future CPGs, which may play a
role in the uptake of CPGs into clinical practice. These el-
ements include enhanced reporting of rigor of develop-
ment, the inclusion of stakeholder preferences and values
and the consideration of context specific factors (e.g., cul-
ture, healthcare setting). Further research on methods to
include patient preferences and how this impacts CPG
content and implementation is needed.
Additional files
Additional file 1: Scope and development group members of CPGs.
(DOCX 20 kb)
Additional file 2: More on DOMAIN 5: applicability. (DOCX 17 kb)
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